CEO update - Monday 7 August

MHRA bilateral

The BIA had a positive face-to-face bilateral meeting with the MHRA last week and it was really reassuring to hear their plans for a busy August addressing companies' concerns about delays and lack of predictability on decisions for clinical trial authorisation applications and amendments. This has been a hot topic for members large and small and I’m pleased that the MHRA’s Clinical Trials Task and Finish Group is meeting this week, where we will be represented by our Head of Regulatory Affairs, Christiane Abouzeid.

The MHRA has increased its clinical trials team to 20, with the appointment of 5 new assessors in recent months, as well as looking at taking on additional expertise to get back up to capacity. Understanding more of how the agency have reallocated work across their teams, evaluated queued initial applications and amendments for complexity, and have changed processes to take a joined-up risk-proportionate approach should help companies to see how the agency is tackling the backlog.

The meeting will be a good chance for a broader group to hear more about how the MHRA has changed its operations to meet the challenge. I stressed how easy it can be for silence to be interpreted negatively and that a much more regular drumbeat of communication on the operational improvements by the agency would be welcomed by the sector – a message the MHRA team I think took to heart.

It’s vital for our sector that the log jam is removed as quickly as possible as it is the key enabling step for the recovery of clinical trials and continued investment into the UK ecosystem for many companies. I know we all wish to see improvements in the performance metrics the agency publishes each month – the next data set will be available next week.  I stressed our communities willingness to help the MHRA so there may be some asks of industry from the MHRA next week.

Our Future of UK Regulation Conference is set to be an important point of engagement and discussion on 5 October featuring representatives from MHRA, HRA, NICE, FDA and industry amongst others.   You can book a place to attend here

British Business Bank seeks Chief Investment Officer  

The BBB have started recruiting for a Chief Investment Officer to lead the Bank’s investment teams - British Patient Capital, British Business Investments and Venture Solutions.

This is a key role for our ecosystem and a unique and really exciting opportunity for an investment professional. The Bank is the largest investor in UK venture capital and drives nationally significant purpose - supporting high potential, innovative businesses essential to UK growth. It would be great if the successful candidate had experience in life science investment and I’d encourage applications from our investment community applications close mid-September.

Health Minister drops in on BIA member as part of summer tour

Good to see Health Minister Will Quince making time to visit BIA member Ochre Bio as part of his summer health tour last week when he was in Oxford. He now understands how this biotech start-up is tackling chronic liver disease - the third leading cause of death in the UK and that they're using advanced genomics and data science to develop RNA medicines which are tested on donated livers.

CEO Update.jpg

I’m off on holiday for a couple of weeks so my next CEO update will be after the Autumn Bank Holiday.  Do look at the exciting range of events we’ve got planned for the autumn and book early to avoid disappointment  - I look forward to seeing you at one of them.


Steve Bates Headshot.png




 Steve Bates OBE
CEO, BioIndustry Association




More news updates 


Macomics expands in Edinburgh, appoints Professor Paul Crocker to SAB

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre.

Evotec opens new state-of-the-art biology facility on Dorothy Crowfoot Hodgkin Campus

Evotec SE today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park.

MicrofluidX welcomes new board members and scientific advisor

MicrofluidX, a UK-based developer of technologies that streamline the development and deployment of cell and gene therapies, today announces the appointment of two new board members and an additional scientific advisor to support the company.

Eagle Genomics raises over £20 million and appoints new leadership

Eagle Genomics is pleased to announce it has raised additional financing of £3 million (USD $4 million) to further deploy its pioneering software platform that enables corporate customers to explore and monetise on microbiome-related research.

Laverock Therapeutics raises £13.5 million to develop gene silencing platform

Laverock Therapeutics announces it has expanded its seed funding round to £13.5 million, led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

Dispatches from the party conferences – Liberal Democrats

In this first instalment of dispatches by the BIA team attending the conferences, Dr. Martin Turner, BIA's Head of Policy and Public Affairs, reports on what he’s heard from the Liberal Democrats.

Discovery Park selects 13 start-ups to join Discovery Spark life science programme

The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Macomics launches fundraising for Prof. Jeffrey Pollard Memorial Fund

Macomics launches Super Triathlon Challenge to raise funds for Prof. Jeffrey Pollard Memorial Fund




More within